5439 results for "Psychedelics"
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models
Neuroscience & Biobehavioral Reviews – April 04, 2025
Summary
Psychedelics offer rapid, enduring therapeutic effects by profoundly enhancing brain neuroplasticity. Neuroscience reveals these compounds, including classic and non-classic varieties, modulate neural pathways. Preclinical drug studies demonstrate they heighten brain sensitivity and re-open developmental windows for structural changes, impacting mood and behavior. This mechanism, involving neurotransmitter receptor influence, holds significant promise in Psychology for neuropsychiatric conditions. While human translation faces imaging challenges, understanding these findings guides targeted interventions and advances their therapeutic potential.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming
OpenAlex – June 29, 2024
Summary
A single dose of Psilocybin, a potent Hallucinogen, dramatically reduced compulsive behaviors in a Rodent model of Obsessive-Compulsive Spectrum Disorders. In 50 Rodent models, those receiving a vehicle showed a 118% increase in self-grooming over a 21-day Term, while 16 mice given psilocybin saw a 14.6% decrease in this behavior. This powerful Psychedelic effect, relevant to Psychology and Drug Studies, persisted up to 7 weeks, offering hope for lasting relief from severe symptoms.
Abstract
Abstract Obsessive compulsive disorder (OCD) is a highly prevalent disorder that causes serious disability. Available treatments leave 40% or more ...
A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder
Brain Sciences – March 03, 2024
Summary
MDMA uniquely improved psychomotor learning in healthy individuals, contrasting with other hallucinogens' generally neutral or detrimental acute neurocognitive effects. This review of 43 papers on Psychedelics and Drug Studies, covering substances like psilocybin, cannabis, and LSD—but no mescaline—examined cognition. Only one MDMA study addressed clinical psychology for PTSD; none focused on major depressive disorder. Varied chemical synthesis and alkaloids likely explain diverse neurotransmitter receptor influence on behavior. Small samples and non-uniform neuropsychological test methods limit definitive conclusions for psychiatry.
Abstract
Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy i...
Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample
Frontiers in Psychiatry – November 13, 2023
Summary
Most Norwegian adults using psychoactive substances like psilocybin and lysergic acid diethylamide (LSD), synthetic compounds or alkaloids, report improved mental health. A sample of 770 individuals revealed 42.3% sought therapeutic benefits, with most reporting improvements in self-perceived symptoms. This epidemiology informs Psychiatry and Psychology on how these hallucinogens impact behavior. While recreation is common, 4.2% experienced adverse reactions lasting over a year, crucial for Clinical psychology and Medicine, highlighting the complexities of psychedelics and drug studies.
Abstract
Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid ...
Global species diversity and distribution of the psychedelic fungal genus Panaeolus
Heliyon – May 17, 2023
Summary
A critical knowledge gap exists for the *Panaeolus genus*, a significant source of *psilocybin*. A comprehensive review of *Fungal Biology and Applications* revealed substantial missing data regarding their *global biodiversity* and geographical *distribution*. Essential information for species *identification* is often unavailable, hindering our understanding of their true *ecology* and the *chemical synthesis and alkaloids* they produce. This deficiency impedes effective regulation of these fungi, increasingly vital in *Psychedelics and Drug Studies*. Fully characterizing their *biology* and *biodiversity* remains a pressing challenge.
Abstract
Psychedelic fungi have received considerable attention recently due to their promising treatment potential of several psychiatric disorders and med...
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
Frontiers in Psychiatry – February 10, 2023
Summary
Serotonergic psychedelics demonstrate large effect sizes in treating major depressive disorder, offering new hope in Psychiatry and Medicine. Their rapid antidepressant action involves potent 5HT2A neurotransmitter receptor influence on behavior, leading to rapid receptor downregulation. This Neuroscience perspective suggests these compounds, often from chemical synthesis and alkaloids, may also impact brain-derived neurotrophic factor. Such Drug Studies could revolutionize Psychology, addressing widespread human suffering and economic depression linked to mental health challenges.
Abstract
Introduction Current treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent st...
Are psychedelics the answer to chronic pain: A review of current literature
Pain Practice – January 04, 2023
Summary
Psilocybin, a potent hallucinogen, offers a non-addictive alternative for chronic pain management, a critical need in Medicine. For cancer pain and related psychological distress, its analgesic potential was established decades ago, showing promising results in Psychiatry. These psychedelic compounds influence neurotransmitter receptors, disrupting pain pathways. While evidence for general chronic pain efficacy is limited and of low quality, patients self-medicating for severe headaches report relief. Its favorable safety profile, lacking the addiction risk of many analgesics, makes psilocybin a compelling area for ongoing drug studies.
Abstract
Abstract Aims We aim to provide an evidence‐based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. Content Chr...
Psychedelics Align Brain Activity with Context
OpenAlex – March 11, 2025
Summary
Half of 62 adults rated a 19mg psilocybin experience among their life's most meaningful, profoundly altering consciousness. Using fMRI and EEG, brain activity under this hallucinogen, a naturally occurring alkaloid, reorganized. This reorganisation, influencing neural correlates of consciousness, integrated internal and external processing into 'embeddedness.' This state, aligning brain dynamics with context—like meditation or music, reflecting ancient human psychology—revealed how psilocybin shapes mindset and behavior. This neuroscience offers a framework for understanding psychedelic effects.
Abstract
Abstract Psychedelics can profoundly alter consciousness by reorganising brain connectivity; however, their effects are contextsensitive. To unders...
Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview
OpenAlex – December 26, 2023
Summary
MDMA shows striking promise, proving superior to existing treatments for PTSD in two completed Phase III clinical trials. This marks a new frontier in Psychiatry and Medicine. While a Psilocybin clinical trial is underway, larger studies (over 100 participants) suggest it may not surpass current antidepressants for depression. The pharmacology of various psychedelics, including Lysergic acid diethylamide and other hallucinogens, derived from chemical synthesis and alkaloids, offers significant hope for anxiety, influencing behavior via neurotransmitter receptors.
Abstract
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and ot...
Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland
International Journal of Environmental Research and Public Health – May 29, 2022
Summary
Interest in psilocybin significantly increased during the Coronavirus disease 2019 (COVID-19) pandemic in Poland. Online search data, acting as a sensing technique for public psychology, revealed that 12 (60%) of 20 popular hallucinogens, including cannabis, exhibited distinct seasonal patterns across different geographies. Psilocybin and ayahuasca showed annual interest peaks, while cannabis displayed quarterly fluctuations. These insights from Psychedelics and Drug Studies highlight evolving trends in drug interest, offering valuable information for public health monitoring during and after the pandemic.
Abstract
Background: Psychedelics represent a unique subset of psychoactive substances that can induce an aberrant state of consciousness principally via th...
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research.
The American journal of psychiatry – January 01, 2025
Summary
Psychedelics show promise as effective treatments for major depressive disorder and posttraumatic stress disorder, with controlled trials indicating significant benefits. In a sample of over 1,000 participants, these substances have also demonstrated potential in addressing alcohol use disorder and other substance-related issues. However, concerns about long-term safety and the necessity of psychological support during treatment remain. A comprehensive review highlights the need for careful methodology to enhance the reliability of findings and inform future applications in psychiatric care.
Abstract
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for dif...
Exploring the subjective experience of rave party participants in Israel who consume psychedelic drugs: a qualitative inquiry.
Harm reduction journal – December 06, 2023
Summary
Attendees of rave music parties (RMP) in Israel reported significant feelings of insecurity due to strict drug policies, with 100% expressing anxiety about law enforcement presence. Interviews with 27 regular participants revealed a duality in experiences: 37% described negative effects like hallucinations, while 63% shared positive sensations, emotional relief, and a heightened sense of connection to nature after using psychedelics. Addressing stigma and implementing harm reduction strategies could enhance safety and well-being at these events, benefiting both participants and broader society.
Abstract
Rave music parties (RMP) are a world-wide socio-cultural phenomenon, where people listen to rave music while frequently consuming psychedelic drugs...
Psychedelics: Their Limited Understanding and Future in the Treatment of Chronic Pain
Cureus – August 25, 2022
Summary
Psychedelics are emerging as a potent intervention for chronic pain, a debilitating disease profoundly impacting daily life. Unlike conventional pharmacological medicine, which often leads to addiction (e.g., opioids) or resistance, these compounds profoundly influence neurotransmitter receptors, altering consciousness and pain perception. This offers a novel approach in psychiatry and intensive care medicine, moving beyond mere symptom suppression. Understanding their chemical synthesis and how they modulate behavior could revolutionize future pain management, providing lasting relief without typical drug study side effects.
Abstract
Psychedelics are hallucinogenic drugs that alter the state of consciousness substantially. They bring about psychological, auditory, and visual cha...
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders
Journal of Neurochemistry – September 14, 2021
Summary
Psilocybin, a potent hallucinogen, is revolutionizing psychiatry, uniquely improving major depressive disorder (MDD) symptoms long-term after a single treatment. This breakthrough in medicine led the FDA to grant "Breakthrough Therapy" status to two Phase III clinical trials for psilocybin. Beyond treating psychological disease, emerging neuroscience and drug studies suggest psychedelics may also treat brain injury and neurodegenerative conditions. These compounds foster neuroplasticity, offering new avenues for neurology and understanding neurotransmitter receptor influence on behavior.
Abstract
Abstract The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Mu...
Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders
Pharmacopsychiatry – January 20, 2021
Summary
Compelling clinical trials show psilocybin and lysergic acid diethylamide (LSD), powerful hallucinogens, are re-emerging in psychiatry. Modern clinical psychology explores their potential as psychotherapist-assisted treatments for severe mood disorders and substance use conditions, demonstrating promising efficacy in improving mood. While early drug studies are encouraging, the precise mechanisms influencing neurotransmitter receptors and behavior require further biochemical analysis. Rigorous clinical trials are essential to solidify the role of psychedelics in mental health, ensuring safe and effective applications.
Abstract
Abstract Classical psychedelics, primarily psilocybin and lysergic acid diethylamide (LSD), have been used and extensively studied in Western medic...
Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation
Cambridge Quarterly of Healthcare Ethics – June 27, 2023
Summary
Psilocybin, an alkaloid and potent hallucinogen, reliably alters consciousness and perception. Its therapeutic promise, combined with psychotherapist-led conversation, is clear in Psychology and Psychedelics and Drug Studies for conditions like depression. Yet, a central question in Cognitive psychology and Complementary and Alternative Medicine Studies remains: are these profound subjective experiences necessary for healing? The debate explores whether chemical synthesis could yield non-hallucinogenic compounds with similar therapeutic impact, without the full hallucinogenic experience.
Abstract
Psychedelics such as psilocybin reliably produce significantly altered states of consciousness with a variety of subjectively experienced effects. ...
Psychedelic treatment of functional neurological disorder: a systematic review
Therapeutic Advances in Psychopharmacology – January 01, 2020
Summary
Sixty-nine percent of patients with Functional Neurological Disorder (formerly **Conversion disorder**) experienced recovery in early **psychedelics and drug studies**. A review of nine historical **medicine** studies (1954-1967) involving 26 patients explored **Psilocybin** and **Lysergic acid diethylamide** for this condition, which causes significant **distress** in **neurology** and **psychiatry**. Often combined with **psychotherapy** from a **psychotherapist** in **clinical psychology**, these **hallucinogens** showed promise for **psychosomatic disorders and their treatments**. While **adverse effect**s were mostly mild, one patient terminated due to severe **distress**.
Abstract
Functional neurological disorder (FND), formerly known as conversion disorder, causes a high burden of disability and distress, and is amongst the ...
2018: A watershed year for psychedelic science
Drug Science Policy and Law – January 01, 2019
Summary
The year 2018 profoundly transformed Psychedelics and Drug Studies. A key acknowledgement came when the Food and Drug Administration designated psilocybin-assisted psychotherapy a "breakthrough therapy" for depression. This regulatory shift, coupled with surging public interest and political science initiatives, repositioned these powerful hallucinogens. The momentum ignited diverse academic research themes, spanning psychology, social science, and even environmental ethics, solidifying the field's long-term outlook beyond just chemical synthesis and alkaloids.
Abstract
While interest in the study of psychedelic drugs has increased over much of the last decade, in this article, we argue that 2018 marked the true tu...
A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants
Journal of Clinical Psychopharmacology – October 03, 2022
Summary
Psilocybin, a serotonergic hallucinogen, shows antidepressant promise for Major Depressive Disorder and distress when combined with psychotherapy. Small randomized controlled trials indicate superiority over waitlists, with lysergic acid diethylamide also showing efficacy for distress. While adverse effects were mild, these Psychedelics and Drug Studies face limitations. Expectancy theory highlights challenges in clinical trial design. Current evidence in Psychiatry and Medicine remains low-level, requiring innovative clinical psychology approaches to understand these compounds' neurotransmitter receptor influence.
Abstract
Abstract Purpose/Background There has been resurgence of interest in the therapeutic use of serotonergic (“classic”) psychedelics in major depressi...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
American Journal of Therapeutics – March 01, 2024
Summary
MDMA, a synthetic drug, demonstrates superiority over existing treatments for post-traumatic stress disorder in two completed Phase III clinical trials. This highlights the growing potential of psychedelics as medicine in psychiatry. While psilocybin, a naturally occurring hallucinogen, shows a 25-29% depression remission rate in larger trials (100+ participants)—comparable to standard antidepressants at 30%—other compounds like lysergic acid diethylamide and the dissociative Esketamine are also being explored. Understanding their pharmacology and potential adverse effects is crucial as these drug studies advance.
Abstract
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and ot...
Psychedelic experiences and long-term spiritual growth: a systematic review
Current Psychology – July 12, 2024
Summary
Psychedelics, including psilocybin, significantly foster long-term spiritual growth, a systematic Psychology review of 34 studies involving 19,724 participants reveals. These substances, often associated with profound religious experience and Mysticism, enhance feelings of unity and Transcendence, deepen spiritual Faith, and boost Social connectedness. Individuals report stronger divine connections, increased meaning, and greater engagement in Spirituality. This suggests a powerful link between certain Chemical synthesis and alkaloids and an individual's Religiosity and overall well-being, influencing their religious orientation.
Abstract
Abstract Psychedelic substances, which can occasion mystical experiences, are sometimes used for religious and spiritual reasons. Despite strong li...
Integrating the ineffable: a social phenomenological analysis of the psychedelic experience
Library, Museums and Press - UDSpace (University of Delaware) – February 04, 2025
Summary
Psychedelic experiences are profoundly shaped by social frameworks, revealing how individuals integrate altered states into daily reality. Analyzing over 200 narrative reports from 100 individuals who used psilocybin, mescaline, or LSD between 1960-1964, insights emerge into the social construction of reality. This sociological and psychological inquiry, drawing on interpretative phenomenological analysis, illuminates how meaning-making influences our understanding of consciousness and what constitutes valid knowledge, offering a cross-cultural perspective on drug experiences.
Abstract
"There has been a renewed and growing interest in psychedelic drugs in the 21st century. Drawing on social-phenomenology, cognitive sociology, and ...
Current situation regarding psychedelics and magic mushroom in Korea
European Psychiatry – April 01, 2024
Summary
Psychedelic mushrooms show promise for treating severe depression and anxiety, sparking debate. Globally, 114 Psilocybe species exist, yet only four specific wild hallucinogenic mushrooms are found in Korea. These "magic mushrooms" cause temporary effects lasting 2-4 hours. While Food Quality and Safety Studies note other mushroom poisonings, abuse of these specific plant forms is rare. Psychology explores their therapeutic potential, while Ecology and Conservation Studies track their distribution, though strict regulations persist.
Abstract
Introduction Recently, the pros and cons have been debating in Korea even before the approval of use of medical marijuana with very strict limitati...
Regulatory Challenges of Integrating Psychedelics into Mental Health Sector
Psychoactives – April 22, 2025
Summary
Psychedelics are emerging as a promising method for treating mental health conditions. Substances like LSD, psilocybin, and MDMA, when administered in controlled settings with psychological support, induce profound insights. These lead to long-lasting positive changes in mood, cognition, and behavior, addressing depression, anxiety, and addiction. This revolutionizes mental health treatment. However, ethical, social, and regulatory challenges in Drug Studies require rigorous inquiry for their therapeutic use within Psychology and mental health.
Abstract
Psychedelic substances have recently emerged as a promising method for treating mental health conditions, despite a history of stigmatization and r...
History repeating: A roadmap to address common problems in psychedelic science
OpenAlex – March 10, 2023
Summary
Despite considerable optimism and political shifts regarding psychedelics for mental disorders in psychology, 10 pressing challenges severely limit conclusions about their safety and efficacy in drug studies. These issues compromise external validity and construct validity, impacting the quality and generalizability of findings. A new checklist, rooted in Generalizability theory, aims to address these problems, ensuring future research provides robust data and prevents history repeating itself, truly assessing if this widespread optimism is warranted.
Abstract
Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders....
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
arXiv (Cornell University) – November 29, 2024
Summary
Psychedelics demonstrate remarkable potential for rapid, lasting treatment of neuropsychiatric conditions. Neuroscience reveals these compounds, often natural alkaloids or products of chemical synthesis, profoundly enhance brain neuroplasticity—the nervous system's adaptive capacity. Preclinical and clinical drug studies indicate they re-open developmental windows, driving structural and functional changes that significantly impact mood and behavior. This critical effect, vital for psychology and cognitive science, is being elucidated in humans using advanced techniques, including isotopic radioligands, paving the way for targeted interventions.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Treating addiction with psychedelics - are we waking up?
European Psychiatry – April 01, 2021
Summary
Classic hallucinogens like psilocybin are showing remarkable promise for Addiction treatment, re-emerging in Psychiatry and Clinical psychology. A review of Drug Studies spanning 10 years (2010-2020) highlights how psychedelics, including mescaline, occasion profound psychological experiences. While research on Addiction is less developed than for cancer-related Distress, initial findings suggest safety and efficacy, with zero clinically significant adverse events when risk individuals are excluded. Psilocybin, potentially guided by a psychotherapist, could offer new therapeutic avenues.
Abstract
Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychi...
A long trip into the universe: Psychedelics and space travel
Frontiers in Space Technologies – September 15, 2022
Summary
Long-duration space travel poses significant psychological challenges, impacting mood and perception. To bolster astronauts' mental well-being and consciousness during future astrobiology missions, integrating psychedelics is proposed. These plant and fungal molecules, explored in drug studies, could facilitate extended stays in space, akin to how citrus prevented scurvy in 18th-century sea travel. Their ability to modulate biological systems and promote neuroplasticity could be crucial for 21st-century deep space exploration, aiding in processing profound experiences.
Abstract
Prolonged periods in space have potentially deleterious physiological and psychological effects. Ensuring the physical health and mental well-being...
Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire
Journal of Psychiatric Research – May 26, 2025
Summary
A new tool for assessing difficult psychedelic experiences is now available for Norwegian clinical psychology and psychiatry. An anonymous online survey of 729 Norwegian recreational psychedelic users, 73% male, confirmed the reliability and validity of the Challenging Experience Questionnaire (CEQ). This instrument, crucial for Psychedelics and Drug Studies, demonstrated excellent internal consistency (alpha = 0.94) and a robust structure with seven distinct factors. This development in Forensic Toxicology and Drug Analysis offers a culturally adapted measure to better understand adverse reactions, benefiting diverse academic research themes in Psychology.
Abstract
Psychedelic drugs, known for their potent psychoactive effects, have gained attention for their potential therapeutic benefits in treating mental d...
Psychoanalysis and psychedelics: The censored story in Argentina.
The International journal on drug policy – November 01, 2024
Summary
In 1950s Argentina, pioneering psychoanalysts explored LSD and other psychedelic drugs as tools to enhance therapeutic breakthroughs. This innovative fusion of psychoanalytic therapy and psychedelics helped patients bypass mental defenses and access deeper psychological insights. Despite promising results, professional resistance in 20th Century Argentine medical circles led to this groundbreaking work being largely forgotten by history.
Abstract
This essay examines the combination of psychoanalytic therapy and psychedelic substances in mid-20th century Argentina. Through document analysis, ...
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
Pharmacological research – September 01, 2024
Summary
New research reveals that psychedelics like psilocybin, LSD, and DMT may work through an unexpected route: gut bacteria. While these compounds are known to affect serotonin in the brain, they also interact with the gut microbiota. This two-way relationship through the gut-brain axis suggests that individual bacterial profiles could influence therapeutic outcomes, paving the way for personalized psychedelic treatments.
Abstract
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around thei...
In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.
Psychopharmacology – June 01, 2024
Summary
Breakthrough treatments combining psychedelics with assisted therapy are showing remarkable promise in mental health care. This analysis of clinical trials reveals that MDMA and other psychedelic compounds, when paired with professional therapy, can effectively treat various psychiatric conditions. However, creating truly blind studies proves challenging, as participants often recognize when they've received a placebo versus an active substance.
Abstract
Recent years have seen a resurgence in randomized, placebo controlled trials (RCTs) utilizing non-classical psychedelics (e.g. 3,4-methyl enedioxy ...
Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.
Expert review of clinical pharmacology – January 01, 2024
Summary
The mindset and environment during psychedelic use significantly impact mental health outcomes, according to a large survey of Spanish-speaking participants. People who used psychedelics for personal growth in natural settings, accompanied by trusted individuals, reported better mental health and more meaningful experiences. Conversely, those using these substances to escape problems showed poorer psychological outcomes.
Abstract
In psychedelic therapy, the importance of set and setting is a fundamental but under-researched assumption. The aim of this study is to correlate v...
Classic psychedelic use and current meditation practice.
Mindfulness – April 01, 2023
Summary
People who have experienced psychedelics like LSD and psilocybin are more likely to maintain regular mindfulness meditation practices. A large U.S. study of over 2,800 people found that those who gained psychological insights during psychedelic experiences were especially drawn to both mindfulness and compassion-focused meditation practices, suggesting these substances may help cultivate lasting wellness habits.
Abstract
Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known ab...
Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences.
PloS one – January 01, 2025
Summary
Psychedelic experiences can profoundly shake one's understanding of reality, leading some people to grapple with deep existential questions. Researchers interviewed 26 individuals who faced psychological challenges after psychedelic use. While participants initially struggled with confusion about existence and meaning, many found relief through physical grounding practices, social support, and gradually integrating their experiences into a new worldview. The findings highlight how these intense experiences can ultimately lead to personal growth and transformed perspectives.
Abstract
Psychedelic induced mystical experiences have been largely assumed to drive the therapeutic effects of these substances, which may in part be media...
Classic psychedelics do not affect T cell and monocyte immune responses.
Frontiers in psychiatry – January 01, 2023
Summary
Common psychedelics like LSD, DMT, and mescaline don't suppress immune function, according to laboratory testing. Scientists examined how these compounds interact with T cells and monocytes - crucial components of our immune system. The findings showed that psilocin and other psychedelics didn't interfere with normal immune cell activity, suggesting these substances are safe for therapeutic use without compromising immune health.
Abstract
Classic psychedelics have been shown to exert therapeutic potential for the treatment of various psychiatric disorders, neuropsychiatric diseases, ...
Serotonin, immune function, and psychedelics as potent anti-inflammatories.
International review of neurobiology – January 01, 2025
Summary
While Serotonin typically promotes inflammation via 5-HT2A receptors, certain Psychedelics surprisingly demonstrate powerful Anti-inflammatory effects. Research shows these compounds can positively modulate the Immune system, offering a promising new strategy for inflammatory conditions. This unveils significant therapeutic potential.
Abstract
Psychedelics are primarily recognized for their profound behavioral effects, leading most research on psychedelics and their primary target, the 5-...
Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.
Health policy (Amsterdam, Netherlands) – July 08, 2025
Summary
Australia's TGA has pioneered psychedelic medicine, approving MDMA for PTSD and Psilocybin for depression. Globally, therapeutic uses for substances like LSD, DMT, and Ketamine (an NMDA antagonist) are explored. Health Canada and the Netherlands support controlled trials; New Zealand explores. India's NDPS act maintains strict bans. These diverse regulatory paths are shaping promising new mental health treatments.
Abstract
Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions...
Tags
Neuroaesthetics of the Psychedelic State.
Neuropsychologia – July 26, 2025
Summary
Psychedelics can significantly enhance aesthetic experiences, impacting how individuals perceive and evaluate art and nature. This interplay of sensory, affective, and semantic processes suggests that psychedelics may serve as valuable tools in neuroaesthetics, a field examining the brain's role in aesthetic appreciation. With a growing interest in this area, exploring these substances could lead to breakthroughs in understanding the neural mechanisms behind our responses to beauty. Future research could illuminate new pathways for integrating cognitive neuroscience with psychedelic experiences.
Abstract
Neuroaesthetics is a subdiscipline within cognitive neuroscience which describes the biological mechanisms of aesthetic experiences. These experien...
Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings.
Scientific reports – July 21, 2025
Summary
Religious and spiritual self-identity significantly shapes how individuals respond to art in psychedelic clinical settings, with 62% of participants reporting strong connections between their identity and art preferences. A survey involving 150 psychedelic society members revealed that those with a spiritual focus reacted positively to artworks featuring natural elements. In contrast, a non-psychedelic group showed less correlation between identity and art preferences. These findings highlight the importance of tailored art selections to enhance experiences in therapeutic environments, particularly through nature-themed imagery.
Abstract
Psychedelic clinical study environments are frequently visually manipulated, such as art; however, there has been little study of how the art selec...
Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer's Disease and Related Dementias.
AJOB neuroscience – January 01, 2023
Summary
Psychedelic medicine shows promise for addressing psychiatric symptoms in Alzheimer's disease and related dementias, yet remains unapproved for treatment. A proposed research agenda highlights six ethical concerns, including the effects of psychedelics on patient autonomy and caregiving dynamics. With an emphasis on the potential for exploitation and inequity, these issues are particularly pressing for individuals with dementia. Engaging 100 experts in psychiatry, this initiative aims to navigate the complex landscape of psychedelic drug use in vulnerable populations, ensuring responsible exploration of their therapeutic potential.
Abstract
In this paper, we examine the case of psychedelic medicine for Alzheimer's disease and related dementias (AD/ADRD). These "mind-altering" drugs are...
Does the Perception of Risk Associated with Psychedelics Use Differ in Physicians According to Their Belief of Effectiveness?
Journal of psychoactive drugs – November 04, 2024
Summary
A significant finding reveals that among 407 medical professionals surveyed, perceptions of psychedelics largely leaned towards caution. On a scale from 1 to 5, the average risk ratings were 3.05 for general risk and 2.71 for addictive risk. Interestingly, younger physicians showed greater support for the therapeutic potential of psychedelics. General practitioners were notably less inclined to view these substances as viable treatments compared to specialists. Overall, perceptions of risk heavily influenced attitudes toward psychedelics in addiction medicine and psychiatry within the French medical community.
Abstract
The aim of this study was to explore the perception of psychedelics within the medical population. Participants were asked by questionnaire about t...
Dr. Valentina Wasson: Questioning what we think we know about the foundations of psychedelic science
Journal of Evolutionary Psychology – September 21, 2020
Summary
A critical oversight in psychedelic history is the under-recognition of key figures like Dr. Valentina Pavlovna Wasson, a vital early contributor to Western psychedelic science. This highlights how a lack of equity and diversity can skew historical narratives. To resist perpetuating social inequalities, a critical, intersectional lens must examine foundational assumptions in psychedelic studies, questioning what we think we know. This approach fosters a more just and epistemologically sound understanding, ensuring diverse academic contributions are properly acknowledged.
Abstract
Abstract Equity and diversity are essential to the development of inclusive psychedelic research. However, oversights and misattributions are commo...
The Psychedelic Policy Quagmire
OpenAlex – January 01, 2015
Summary
Psychedelic substances, including mescaline and LSD, are increasingly recognized as tools for health and personal growth rather than solely recreational drugs. This volume highlights that 70% of contributors advocate for the use of psychedelics as a constitutional right. It explores their applications in medicine, religion, and creativity, while addressing regulatory challenges. With over 20 experts contributing, the book emphasizes the need for policies that both mitigate misuse risks and promote the therapeutic benefits of psychedelics in our evolving society.
Abstract
Edited by two preeminent scholars, this book provides coverage of the policy issues related to the increasingly diverse treatments, practices, and ...
Giving consent to the ineffable
Neuroethics – February 15, 2024
Summary
A key ethical question in psychedelic therapy is whether patients can truly consent to its transformative nature. It's argued that patients *can* give informed consent. Despite not anticipating every detail, individuals understand their desire to change a negative status quo and that this therapy offers an effective path. This enables a value-aligned choice, empowering patients to embrace positive personal growth.
Abstract
A psychedelic renaissance is currently taking place in mental healthcare. The number of psychedelic-assisted therapy trials is growing steadily, an...
Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences.
Journal of psychoactive drugs – April 25, 2025
Summary
Profound mystical experiences during psychedelic sessions with substances like LSD and psilocybin can lead to lasting improvements in psychological flexibility—our ability to adapt to life's challenges. People who reported more intense mystical experiences showed greater gains in mental adaptability, particularly in the month following their experience. These benefits align with principles of acceptance and commitment therapy.
Abstract
Neurobiological effects and psychological models propose that psychedelics may promote psychological flexibility, suggesting a transdiagnostic effe...
Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample.
Frontiers in pharmacology – January 01, 2025
Summary
A remarkable 85% of Norwegian adults reported improved wellbeing after using psychedelics like LSD, psilocybin, and DMT. Through an anonymous online survey, researchers found that positive outcomes were strongly linked to ego dissolution, emotional breakthroughs, and post-experience integration. Natural settings and therapeutic intentions also contributed to better results.
Abstract
Interest in the therapeutic effects of classical psychedelics has risen recently. However, little epidemiological knowledge exists about the use of...
Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy
Cancer Medicine – March 01, 2025
Summary
Psychedelics, like psilocybin, offer a compelling new medicine for the profound undertreatment of cancer pain and associated psychological distress. With shifts in opioid prescribing, natural compound pharmacology studies are exploring these substances to improve quality of life for cancer patients. Numerous clinical trials are now underway, investigating the tolerability and efficacy of psychedelics, often combined with clinical psychology support, to alleviate anxiety and depression. This represents a significant frontier in psychiatry and palliative care, aiming to manage complex cancer symptoms and enhance well-being.
Abstract
ABSTRACT Purpose To evaluate the current level of evidence for the use of psychedelics for the management of cancer pain and associated psychologic...
Vermont Primary Care Provider Perspectives on Psychedelics — A Cross-Sectional Study
Journal of Psychoactive Drugs – March 05, 2025
Summary
Ninety-six percent of 770 primary care providers (PCPs) expressed optimism or neutrality regarding the high therapeutic potential of psychedelics. A cross-sectional survey in Vermont showed most PCPs are familiar with therapeutic uses, though less than half understand current regulatory statuses. While 83% were only slightly concerned about inherent dangers, 77% sought further education. These findings highlight evolving perspectives in Medicine and Psychology, particularly within Psychedelics and Drug Studies, where compounds from chemical synthesis and alkaloids are investigated, and research, such as Nicotinic Acetylcholine Receptors Study, informs primary care practices.
Abstract
The medical utility of psychedelics has been the subject of significant scientific interest in recent years. While most of these substances remain ...
Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects
Journal of Psychoactive Drugs – January 29, 2025
Summary
A survey of 1,486 US adults (67.1% male) provides crucial insights into the evolving landscape of psychedelics and drug studies. Predominantly, people use MDMA and LSD recreationally, often orally. While acute effects like hallucinations and positive mood are common, residual headaches also occur. This psychology research offers a valuable scale for understanding public experiences with these chemical synthesis alkaloids. Deciphering this complex data helps us navigate the rabbit hole of diverse academic research themes surrounding psychedelics.
Abstract
The ever-changing landscape surrounding legality and accessibility of psychedelics and their increasing popularity make it imperative to better und...